{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:54:50Z","timestamp":1792065290926,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejps.2020.105680","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T19:32:57Z","timestamp":1608665577000},"page":"105680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The effect of particle size of inhaled tobramycin dry powder on the eradication of Pseudomonas aeruginosa biofilms"],"prefix":"10.1016","volume":"158","author":[{"given":"Reham","family":"Aljalamdeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Bolhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105680_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620905279","article-title":"Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin","volume":"14","author":"Akkerman-Nijland","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ejps.2020.105680_bib0002","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2018.07.030","article-title":"Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties","volume":"123","author":"Ambrus","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2020.105680_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","article-title":"Determination of minimum inhibitory concentrations","volume":"48","author":"Andrews","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2020.105680_bib0004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/jamp.2015.1220","article-title":"Effect of flow rate on in vitro aerodynamic performance of NEXThaler\u00ae in comparison with Diskus\u00ae and Turbohaler\u00ae dry powder inhalers","volume":"29","author":"Buttini","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejps.2020.105680_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.addr.2014.11.017","article-title":"Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients","volume":"85","author":"Ciofu","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejps.2020.105680_bib0006","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.scitotenv.2017.08.240","article-title":"Particle deposition in tracheobronchial airways of an infant, child and adult","volume":"612","author":"Deng","year":"2018","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.ejps.2020.105680_bib0007","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1128\/AAC.02533-15","article-title":"Impairment of Pseudomonas aeruginosa biofilm resistance to antibiotics by combining the drugs with a new quorum-sensing inhibitor","volume":"60","author":"Furiga","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2020.105680_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel Tobramycin Inhalation Powder in Cystic Fibrosis Subjects: Pharmacokinetics and Safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ejps.2020.105680_bib0009","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology","volume":"24","author":"Geller","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejps.2020.105680_bib0010","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1002\/jps.21203","article-title":"Comparison of delivery characteristics from a combination metered-dose inhaler using the Andersen cascade impactor and the next generation pharmaceutical impactor","volume":"97","author":"Guo","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105680_bib0011","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1099\/mic.0.000352","article-title":"An ex vivo lung model to study bronchioles infected with Pseudomonas aeruginosa biofilms","volume":"162","author":"Harrison","year":"2016","journal-title":"Microbiology"},{"key":"10.1016\/j.ejps.2020.105680_bib0012","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jcf.2014.04.004","article-title":"Inhaled versus nebulised tobramycin: a real world comparinson in adult cystic fibrosis (CF)","volume":"13","author":"Harrison","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejps.2020.105680_bib0013","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1128\/IAI.73.4.2504-2514.2005","article-title":"Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis","volume":"73","author":"Hoffmann","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejps.2020.105680_bib0014","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1741-7015-9-32","article-title":"Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis","volume":"9","author":"Hoiby","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.ejps.2020.105680_bib0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jcf.2009.07.001","article-title":"Pharmacokinetics and safety of tobramycin administered by the PARI eFlow\u00ae rapid nebulizer in cystic fibrosis","volume":"8","author":"Hubert","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ejps.2020.105680_bib0016","series-title":"Validation of analytical procedures: Text and Methodology","year":"1996"},{"key":"10.1016\/j.ejps.2020.105680_bib0017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2005.11.013","article-title":"Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs","volume":"111","author":"Jinno","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2020.105680_bib0018","first-page":"e3857","article-title":"Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung","author":"Kirchner","year":"2012","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejps.2020.105680_bib0019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejps.2020.105680_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1258\/la.2007.06014e","article-title":"Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies","volume":"42","author":"Kukavica-Ibrulj","year":"2008","journal-title":"Lab. Anim."},{"key":"10.1016\/j.ejps.2020.105680_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/9780471729259.mc06e01s25","article-title":"Growth and laboratory maintenance of Pseudomonas aeruginosa","volume":"25","author":"LaBauve","year":"2012","journal-title":"Curr. Protoc. Microbiol."},{"key":"10.1016\/j.ejps.2020.105680_bib0022","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.jaci.2009.09.050","article-title":"Particle size of inhaled corticosteroids: Does it matter?","volume":"124","author":"Leach","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejps.2020.105680_bib0023","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1574-695X.1996.tb00253.x","article-title":"Ribotyping of Pseudomonas aeruginosa isolates from patients and water springs and genome fingerprinting of variants concerning mucoidy","volume":"13","author":"Leit\u00e3o","year":"1996","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.ejps.2020.105680_bib0024","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/jps.23955","article-title":"Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles\/nanoparticles for targeted pulmonary delivery as dry powder inhalers","volume":"103","author":"Li","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105680_bib0025","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.2147\/IJN.S87143","article-title":"Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation","volume":"10","author":"Liu","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2020.105680_bib0026","first-page":"283","article-title":"Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part I: Design","volume":"16","author":"Marple","year":"2003","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejps.2020.105680_bib0027","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijpharm.2016.09.034","article-title":"Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin","volume":"514","author":"Marshall","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105680_bib0028","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1073\/pnas.0711982105","article-title":"Dynamics of Pseudomonas aeruginosa genome evolution","volume":"105","author":"Mathee","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejps.2020.105680_bib0029","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s40265-013-0141-0","article-title":"Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"73","author":"McKeage","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2020.105680_bib0030","first-page":"275","volume":"8","author":"Meenach","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.ejps.2020.105680_bib0031","article-title":"Growing and analyzing static biofilms","volume":"1","author":"Merritt","year":"2005","journal-title":"Curr. Protoc. Microbiol., Ch"},{"key":"10.1016\/j.ejps.2020.105680_bib0032","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1021\/acs.molpharmaceut.7b00036","article-title":"Physical characterization of tobramycin inhalation powder: II. State diagram of an amorphous engineered particle formulation","volume":"14","author":"Miller","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2020.105680_bib0033","doi-asserted-by":"crossref","first-page":"17629","DOI":"10.1038\/s41598-017-17772-6","article-title":"Increasing the permeability of Escherichia coli using MAC13243","volume":"7","author":"Muheim","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2020.105680_bib0034","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2014.06.055","article-title":"Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors","volume":"192","author":"Nafee","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2020.105680_bib0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1574-6976.2011.00290.x","article-title":"Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria","volume":"36","author":"Nikaido","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"issue":"Suppl 2","key":"10.1016\/j.ejps.2020.105680_bib0036","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1089\/jamp.2010.0836","article-title":"The particle has landed - characterizing the fate of inhaled pharmaceuticals","volume":"23","author":"Patton","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"Suppl 1","key":"10.1016\/j.ejps.2020.105680_bib0037","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00148581-200709001-00002","article-title":"Clinical Pharmacology Study of Bramitob\u00ae, a Tobramycin Solution for Nebulization","volume":"9","author":"Poli","year":"2007","journal-title":"Comparison with Tobi\u00ae. Pediatr. Drugs."},{"key":"10.1016\/j.ejps.2020.105680_bib0038","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1208\/s12248-020-0422-y","article-title":"Development of an Aerosol dose Collection Apparatus for in vitro dissolution measurements of orally inhaled drug products","volume":"22","author":"Price","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2020.105680_bib0039","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1208\/s12249-012-9822-3","article-title":"Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs)","volume":"13","author":"Riley","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2020.105680_bib0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1208\/s12249-013-9936-2","article-title":"The effect of nonideal cascade impactor stage collection efficiency curves on the interpretation of the size of inhaler-generated aerosols","volume":"14","author":"Roberts","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2020.105680_bib0041","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11095-018-2544-9","article-title":"Measuring the bipolar charge distributions of fine particle aerosol clouds of commercial PMDI suspensions using a bipolar Next Generation Impactor (bp-NGI)","volume":"36","author":"Rowland","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105680_bib0042","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejps.2020.105680_bib0044","doi-asserted-by":"crossref","first-page":"e00545","DOI":"10.1002\/mbo3.545","article-title":"Meloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by Pseudomonas aeruginosa","volume":"7","author":"She","year":"2018","journal-title":"Microbiologyopen"},{"key":"10.1016\/j.ejps.2020.105680_bib0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11095-006-9146-7","article-title":"Particle size analysis in pharmaceutics: principles, methods and applications","volume":"24","author":"Shekunov","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105680_bib0046","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/35023079","article-title":"Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen","volume":"406","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2020.105680_bib0047","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijpharm.2018.04.048","article-title":"Dissolution of fine particle fraction from truncated Anderson Cascade Impactor with an enhancer cell","volume":"545","author":"Tay","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105680_bib0048","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00090314","article-title":"Inhaled antibiotics: dry or wet?","volume":"44","author":"Tiddens","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejps.2020.105680_bib0049","doi-asserted-by":"crossref","DOI":"10.1080\/20018525.2017.1369328","article-title":"Targeting the small airways with dry powder adenosine: a challenging concept","volume":"4","author":"van der Wiel","year":"2017","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.ejps.2020.105680_bib0050","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1368-5031.2004.00274.x","article-title":"The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (Part 2): Clinical experience in children","volume":"58","author":"Van Schayck","year":"2004","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejps.2020.105680_bib0051","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1067\/mai.2000.111582","article-title":"Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma","volume":"106","author":"Vanden Burgt","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejps.2020.105680_bib0052","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jaci.2006.04.056","article-title":"The functional benefit of anti-inflammatory aerosols in the lung periphery","volume":"118","author":"Verbanck","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejps.2020.105680_bib0053","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2017.09.047","article-title":"Design and pharmaceutical applications of a low-flow-rate single-nozzle impactor","volume":"533","author":"Wang","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105680_bib0054","series-title":"Controlled Pulmonary Drug Delivery","first-page":"335","article-title":"Nanoparticles for Pulmonary Delivery","author":"Watts","year":"2011"},{"key":"10.1016\/j.ejps.2020.105680_bib0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1574-6976.2000.tb00565.x","article-title":"Heterogeneity in biofilms","volume":"24","author":"Wimpenny","year":"2000","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ejps.2020.105680_bib0056","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI0213870","article-title":"Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients","volume":"109","author":"Worlitzsch","year":"2002","journal-title":"J. Clin. Invest."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720304681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720304681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:55:43Z","timestamp":1760529343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720304681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":55,"alternative-id":["S0928098720304681"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105680","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of particle size of inhaled tobramycin dry powder on the eradication of Pseudomonas aeruginosa biofilms","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105680"}}